tiprankstipranks
Concord Medical Services (CCM)
NYSE:CCM

Concord Medical Services (CCM) AI Stock Analysis

107 Followers

Top Page

CCM

Concord Medical Services

(NYSE:CCM)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 5.2)
Rating:44Neutral
Price Target:
$4.50
▼(-6.25% Downside)
Action:DowngradedDate:01/27/26
The score is primarily weighed down by severe financial stress (declining revenue, persistent losses, negative equity, and negative operating/free cash flow). Technicals are only neutral and do not offset the weak fundamentals, while valuation is constrained by a negative P/E and lack of dividend support.
Positive Factors
Market Position
CCM's positioning as a leading provider of cancer treatment and diagnostics in China indicates durable demand and scale advantages. A broad network of centers supports referral flows, payer relationships and operational leverage that can sustain volume and service breadth over the medium term.
Negative Factors
Revenue and Margin Erosion
A steep revenue decline combined with negative gross profit and EBIT margins undermines the business's ability to cover fixed costs and invest in equipment and personnel. Persistent top-line contraction threatens long-term scale economics and could force service reductions or restructurings.
Read all positive and negative factors
Positive Factors
Negative Factors
Market Position
CCM's positioning as a leading provider of cancer treatment and diagnostics in China indicates durable demand and scale advantages. A broad network of centers supports referral flows, payer relationships and operational leverage that can sustain volume and service breadth over the medium term.
Read all positive factors

Concord Medical Services (CCM) vs. SPDR S&P 500 ETF (SPY)

Concord Medical Services Business Overview & Revenue Model

Company Description
Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services inc...
How the Company Makes Money
Concord Medical Services generates revenue primarily through its cancer treatment services, including radiation therapy, diagnostic imaging, and related healthcare services. The company charges patients and insurance providers for these services, ...

Concord Medical Services Financial Statement Overview

Summary
Very weak fundamentals: revenue fell sharply ($537M in 2023 to $384M in 2024), margins are negative (gross profit and EBIT), and net losses persist. The balance sheet shows solvency risk with negative stockholders’ equity and liabilities exceeding assets. Cash flow remains strained with negative operating and free cash flow, indicating reliance on external financing.
Income Statement
15
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
20
Very Negative
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue365.76M383.96M537.40M472.08M485.63M223.01M
Gross Profit-41.85M-79.16M-76.61M-152.41M-56.90M13.08M
EBITDA-358.51M-345.62M-344.16M-401.86M-363.86M-236.72M
Net Income-163.12M-308.24M-297.66M-489.66M-271.43M-309.99M
Balance Sheet
Total Assets6.73B6.73B6.05B6.00B6.23B5.33B
Cash, Cash Equivalents and Short-Term Investments177.39M350.85M58.14M158.28M157.39M334.26M
Total Debt3.82B3.93B3.30B3.24B2.73B2.35B
Total Liabilities5.01B5.11B4.31B3.99B3.49B2.93B
Stockholders Equity-2.24B-2.28B-2.12B-1.86B-1.37B-662.96M
Cash Flow
Free Cash Flow0.00-808.58M-392.17M-600.47M-1.12B-734.47M
Operating Cash Flow0.00-397.75M-276.47M-216.69M-359.31M-229.77M
Investing Cash Flow0.00-593.44M-47.68M-118.79M-565.98M-533.88M
Financing Cash Flow0.001.15B257.65M383.09M642.45M1.14B

Concord Medical Services Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.80
Price Trends
50DMA
3.84
Positive
100DMA
4.05
Negative
200DMA
4.81
Negative
Market Momentum
MACD
0.02
Negative
RSI
54.92
Neutral
STOCH
73.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Positive. The current price of 4.8 is above the 20-day moving average (MA) of 3.78, above the 50-day MA of 3.84, and below the 200-day MA of 4.81, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 54.92 is Neutral, neither overbought nor oversold. The STOCH value of 73.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCM.

Concord Medical Services Risk Analysis

Concord Medical Services disclosed 78 risk factors in its most recent earnings report. Concord Medical Services reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Concord Medical Services Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$121.38M45.39-3.70%-54.93%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
$56.29M-0.16-71.45%-47.03%-274.41%
47
Neutral
$18.54M-0.04-257.39%-2.15%-6.72%
44
Neutral
$16.98M-0.11-22.38%56.66%
44
Neutral
$8.91M-8.99-8.75%17.84%-156.13%
43
Neutral
$29.32M-13.2215.27%11.14%-0.29%94.56%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CCM
Concord Medical Services
3.91
-0.48
-10.93%
AMS
American Shared Hospital Services
1.35
-1.49
-52.46%
JYNT
Joint
8.60
-1.88
-17.94%
CCEL
Cryo-Cell International
3.64
-1.69
-31.73%
DCGO
DocGo
0.57
-1.97
-77.56%
PIII
P3 Health Partners
2.57
-5.93
-69.76%

Concord Medical Services Corporate Events

Concord Medical Announces 2025 Shareholder Meeting
Dec 2, 2025
On December 2, 2025, Concord Medical Services announced its 2025 annual general meeting of shareholders scheduled for December 29, 2025, in Beijing. The meeting will not involve any proposals for shareholder approval but will serve as a platform f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 27, 2026